While big names get the spotlight, smaller healthcare stocks often hold the most explosive upside. Joel Lim from Becoin.net highlights two small-cap firms.
NanoMed Therapeutics and Synaptogenix that could deliver huge gains by 2026.
-
NanoMed Therapeutics
NanoMed Therapeutics (NASDAQ: NMTX) is using nanoparticles to deliver chemo directly to tumors, cutting side effects and boosting effectiveness by up to 15x at the tumor site. In recent trials, pancreatic cancer patients saw a 40% delay in disease progression.
It’s shifting from R&D to revenue, thanks to a $120M Roche partnership and 210% YoY growth to $18.7M in Q2. It has FDA Fast Track and plans to file for approval in early 2025. At $850M market cap, it’s small compared to its long-term potential.
Joel Lim says, “NanoMed isn’t just about cancer, its delivery tech could expand to other diseases. Growth could mimic Moderna’s early breakout years.”
-
Synaptogenix
Synaptogenix (NASDAQ: SNPX) is targeting brain repair for diseases like Alzheimer’s and Parkinson’s. Its lead drug, Bryostatin-1, showed a 35% boost in cognition and a 50% cut in motor issues—better than current treatments.
A $75M licensing deal with a top pharma firm supports Phase III trials. Synaptogenix holds 12 patents and has tripled its cash reserves to $180M. Costs are dropping as trials simplify.
Joel Lim says, “Brain diseases are a $150B market. If Synaptogenix captures even 10%, its current $620M valuation could look tiny.”
I’m available for interviews or to provide deeper context on this topic. Get in touch anytime.
Leave a Comment